A multi-centre phase II trial to assess the efficacy of epirubicin, cisplatin and capecitabine in carcinomas of unknown primary (CUP): incorporating the prospective validation of molecular classifiers in diagnosis and classification and exploratory metabonomics.

Trial Profile

A multi-centre phase II trial to assess the efficacy of epirubicin, cisplatin and capecitabine in carcinomas of unknown primary (CUP): incorporating the prospective validation of molecular classifiers in diagnosis and classification and exploratory metabonomics.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Epirubicin (Primary)
  • Indications Cancer
  • Focus Biomarker; Diagnostic use
  • Acronyms CUP ONE
  • Most Recent Events

    • 13 Dec 2013 Accrual to date is 114% according to United Kingdom Clinical Research Network.
    • 23 Nov 2013 Accrual to date is 109% according to United Kingdom Clinical Research Network.
    • 24 Oct 2013 Accrual to date is 103% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top